Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma(379 views visite) Fonti R, Larobina M, Del Vecchio S, Fabbricini R, Catalano L, Pane F, Salvatore M, Pace L
Keywords Parole chiave: Adult, Aged, 80 And Over, Female, Fluorodeoxyglucose F18, Diagnostic Use, Glycolysis, Humans, Middle Aged, Multimodal Imaging, Multiple Myeloma, Metabolism, Pathology, Radionuclide Imaging, Positron-Emission Tomography, Prognosis, Retrospective Studies, Survival Analysis, X-Ray Computed, Tumor Burden, Fluorodeoxyglucose F18 Diagnostic Use, Multiple Myeloma Metabolism Pathology Radionuclide Imaging, 18f-Fdg-Pet Ct, Metabolic Tumor Volume, Albumin, Beta 2 Microglobulin, Bortezomib, Fluorodeoxyglucose F 18, Hemoglobin, Lenalidomide, M Protein, Thalidomide, Article, Bone Marrow Transplantation, Cancer Growth, Cancer Mortality, Cancer Prognosis, Cancer Staging, Cancer Survival, Clinical Article, Computer Assisted Emission Tomography, Diagnostic Imaging, Drug Tumor Level, Follow Up, Lymphocytic Infiltration, Overall Survival, Plasma Cell, Prediction, Priority Journal, Scoring System, Three Dimensional Imaging, Positron-Emission Tomography And Computed Tomography, Multiple Myeloma Diagnostic Imaging Metabolism Pathology,
Affiliations Affiliazioni: *** IBB - CNR ***
Institute of Biostructures and Bioimages-National Research Council, University Federico II, Naples, Italy. fontir@tin.it, Department of Biomorphological and Functional Sciences, University Federico II, Naples, Italy Department of Hematology, University Federico II, Naples, Italy Department of Medicine and Surgery, University of Salerno, Salerno, Italy
References Riferimenti: Malpas, J.S., Caroll, J.J., Myeloma: Clinical presentation and diagnosis (1995) Myeloma: Biology and Management, p. 169. , Malpas JS, Bergsagel DE, Kyle RA, eds. New York, NY: Oxford University Pres
Drach, J., Sagaster, V., Ackermann, J., Kaufmann, H., Prognostic factors for multiple myeloma (2006) Hematology, 2, pp. 196-200
Kyle, R.A., Rajkumar, S.V., Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma (2009) Leukemia, 23, pp. 3-9
Durie, B.G., Salmon, S.E., A clinical staging system for multiple myeloma: Correlation of measured myeloma cells mass with presenting clinical features, response to treatment and survival (1975) Cancer, 36, pp. 842-854
Durie, B.G.M., Kyle, R.A., Belch, A., Bensinger, W., Blade, J., Boccadoro, M., Child, J.A., Van Ness, B., Myeloma management guidelines: A consensus report from the Scientific Advisors of the International Myeloma Foundation (2003) Hematology Journal, 4 (6), pp. 379-398. , DOI 10.1038/sj.thj.6200312
Durie, B.G.M., The role of anatomic and functional staging in myeloma: Description of Durie/Salmon plus staging system (2006) European Journal of Cancer, 42 (11), pp. 1539-1543. , DOI 10.1016/j.ejca.2005.11.037, PII S0959804906003236
La, T.H., Filion, E.J., Turnbull, B.B., Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer (2009) Int J Radiat Oncol Biol Phys, 74, pp. 1335-1341
Ahn, P.H., Garg, M.K., Positron Emission Tomography/Computed Tomography for Target Delineation in Head and Neck Cancers (2008) Seminars in Nuclear Medicine, 38 (2), pp. 141-148. , DOI 10.1053/j.semnuclmed.2007.11.002, PII S0001299807001407
Lee, P., Weerasuriya, D.K., Lavori, P.W., Quon, A., Hara, W., Maxim, P.G., Le, Q.-T., Loo Jr., B.W., Metabolic Tumor Burden Predicts for Disease Progression and Death in Lung Cancer (2007) International Journal of Radiation Oncology Biology Physics, 69 (2), pp. 328-333. , DOI 10.1016/j.ijrobp.2007.04.036, PII S0360301607006827
Erdi, Y.E., Mawlawi, O., Larson, S.M., Imbriaco, M., Yeung, H., Finn, R., Humm, J.L., Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding (1997) Cancer, 80 (12 SUPPL.), pp. 2505-2509
Basu, S., Saboury, B., Torigian, D.A., Alavi, A., Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: Emerging significance of image segmentation and global disease assessment (2011) Mol Imaging Biol, 13, pp. 801-811
Chung, M.K., Jeong, H.S., Park, S.G., Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer (2009) Clin Cancer Res, 15, pp. 5861-5868
Wang, W., Larson, S.M., Fazzari, M., Prognostic value of18F-fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer (2000) J Clin Endocrinol Metab, 85, pp. 1107-1113
Berkowitz, A., Basu, S., Srinivas, S., Sankaran, S., Schuster, S., Alavi, A., Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: A novel approach with fluorodeoxyglucose-PET (2008) Nuclear Medicine Communications, 29 (6), pp. 521-526. , DOI 10.1097/MNM.0b013e3282f813a4, PII 0000623120080600000003
Cazaentre, T., Morschhauser, F., Vermandel, M., Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma (2010) Eur J Nucl Med Mol Imaging, 37, pp. 494-504
Costelloe, C.M., Macapinlac, H.A., Madewell, J.E., 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma (2009) J Nucl Med, 50, pp. 340-347
Cheon, G.J., Kim, M.S., Lee, J.A., Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI (2009) J Nucl Med, 50, pp. 1435-1440
Benz, M.R., Allen-Auerbach, M.S., Eilber, F.C., Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas (2008) J Nucl Med, 49, pp. 1579-1584
Smith, A., Wisloff, F., Samson, D., Guidelines on the diagnosis and management of multiple myeloma 2005 (2006) Br J Haematol, 132, pp. 410-451. , UK Myeloma Forum
Nordic Myeloma Study Group
British Committee for Standards in Haematology
Terpos, E., Moulopoulos, L.A., Dimopoulos, M.A., Advances in imaging and the management of myeloma bone disease (2011) J Clin Oncol, 29, pp. 1907-1915
Zamagni, E., Patriarca, F., Nanni, C., Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation (2011) Blood, 118, pp. 5989-5995
Fonti, R., Salvatore, B., Quarantelli, M., 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma (2008) J Nucl Med, 49, pp. 195-200
Bird, J.M., Owen, R.G., D'Sa, S., Guidelines on the diagnosis and management of multiple myeloma 2011 (2011) Br J Haematol, 154, pp. 32-75. , Haemato-oncology Task Force of the British Committee for Standards in Haematology and UK Myeloma Forum
Dimopoulos, M., Terpos, E., Comenzo, R.L., International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma (2009) Leukemia, 23, pp. 1545-1556. , IMWG
Bartel, T.B., Haessler, J., Brown, T.L., F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma (2009) Blood, 114, pp. 2068-2076
Lütje, S., De Rooy, J.W., Croockewit, S., Koedam, E., Oyen, W.J., Raymakers, R.A., Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma (2009) Ann Hematol, 88, pp. 1161-1168
Nanni, C., Zamagni, E., Farsad, M., Role of18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: Preliminary results (2006) Eur J Nucl Med Mol Imaging, 33, pp. 525-531
Zamagni, E., Nanni, C., Patriarca, F., A prospective comparison of18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma (2007) Haematologica, 92, pp. 50-55
Hanin, F.X., Lonneux, M., Cornet, J., Prognostic value of FDG uptake in early stage non-small cell lung cancer (2008) Eur J Cardiothorac Surg, 33, pp. 819-823
Berghmans, T., Dusart, M., Paesmans, M., Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): A systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project (2008) J Thorac Oncol, 3, pp. 6-12. , European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project
Grgic, A., Yüksel, Y., Gröschel, A., Risk stratification of solitary pulmonary nodules by means of PET using18F-fluorodeoxyglucose and SUV quantification (2010) Eur J Nucl Med Mol Imaging, 37, pp. 1087-1094
Chatterton, B.E., Ho Shon, I., Baldey, A., Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: Results of a multicentre prospective study (2009) Eur J Nucl Med Mol Imaging, 36, pp. 354-361
Xie, P., Li, M., Zhao, H., Sun, X., Fu, Z., Yu, J., 18F-FDG PET or PET-CT to evaluate prognosis for head and neck cancer: A meta-analysis (2011) J Cancer Res Clin Oncol, 137, pp. 1085-1093
Namura, K., Minamimoto, R., Yao, M., Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: A preliminary report (2010) BMC Cancer, 10, pp. 667-674
Haznedar, R., Aki, S.Z., Akdemir, O.U., Value of18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma (2011) Eur J Nucl Med Mol Imaging, 38, pp. 1046-1053
Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma
Kim YH, Shin SW, Pellicano R, Fagoonee S, Choi IJ, Kim YI, Park B, Choi JM, Kim SG, Choi J, Park JY, Oh S, Yang HJ, Lim JH, Im JP, Kim JS, Jung HC, Ponzetto A, Figura N, Malfertheiner P, Choi IJ, Kook MC, Kim YI, Cho SJ, Lee JY, Kim CG, Park B, Nam BH, Bae SE, Choi KD, Choe J, Kim SO, Na HK, Choi JY, Ahn JY, Jung KW, Lee J, Kim DH, Chang HS, Song HJ, Lee GH, Jung HY, Seta T, Takahashi Y, Noguchi Y, Shikata S, Sakai T, Sakai K, Yamashita Y, Nakayama T, Leja M, Park JY, Murillo R, Liepniece-karele I, Isajevs S, Kikuste I, Rudzite D, Krike P, Parshutin S, Polaka I, Kirsners A, Santare D, Folkmanis V, Daugule I, Plummer M, Herrero R, Tsukamoto T, Nakagawa M, Kiriyama Y, Toyoda T, Cao X, Corral JE, Mera R, Dye CW, Morgan DR, Lee YC, Lin JT, Garcia Martin R, Matia Cubillo A, Lee SH, Park JM, Han YM, Ko WJ, Hahm KB, Leontiadis GI, Ford AC, Ichinose M, Sugano K, Jeong M, Park JM, Han YM, Park KY, Lee DH, Yoo JH, Cho JY, Hahm KB, Bang CS, Baik GH, Shin IS, Kim JB, Suk KT, Yoon JH, Kim YS, Kim DJ * Helicobacter pylori Eradication for Prevention of Metachronous Recurrence after Endoscopic Resection of Early Gastric Cancer(217 visite) N Engl J Med (ISSN: 0028-4793, 0028-4793linking, 1533-4406electronic), 2015 Jun; 30642104201566393291: 749-756. Impact Factor:59.558 DettagliEsporta in BibTeXEsporta in EndNote
Santulli G, Cipolletta E, Sorriento D, Del Giudice C, Anastasio A, Monaco S, Maione AS, Condorelli G, Puca A, Trimarco B, Illario M, Iaccarino G * CaMK4 gene deletion induces hypertension(284 visite) J Am Heart Assoc Journal Of The American Heart Association (ISSN: 2047-9980), 2012; 1(4): N/D-N/D. Impact Factor:2.882 DettagliEsporta in BibTeXEsporta in EndNote
Antonini A, Vitale C, Barone P, Cilia R, Righini A, Bonuccelli U, Abbruzzese G, Ramat S, Petrone A, Quatrale R, Marconi R, Ceravolo R, Stefani A, Lopiano L, Zappia M, Capus L, Morgante L, Tamma F, Tinazzi M, Colosimo C, Guerra UP, Valzania F, Fagioli G, Distefano A, Bagnato A, Feggi L, Anna S, Maria Teresa Rosaria De Cr, Nobili F, Mazzuca N, Baldari S, Eleopra R, Bestetti A, Benti R, Varrone A, Volterrani D, Massa R, Stocchi F, Schillaci O, Dore F, Zibetti M, Castellano G, Battista SG, Giorgetti G * The relationship between cerebral vascular disease and parkinsonism: The VADO study(422 visite) Parkinsonism Relat D (ISSN: 1353-8020, 1873-5126, 1873-5126electronic), 2012; 18(6): 775-780. Impact Factor:3.274 DettagliEsporta in BibTeXEsporta in EndNote
Bruni AC, Bernardi L, Colao R, Rubino E, Smirne N, Frangipane F, Terni B, Curcio SA, Mirabelli M, Clodomiro A, Di Lorenzo R, Maletta R, Anfossi M, Gallo M, Geracitano S, Tomaino C, Muraca MG, Leotta A, Lio SG, Pinessi L, Rainero I, Sorbi S, Nee L, Milan G, Pappata S, Postiglione A, Abbamondi N, Forloni G, St George Hyslop P, Rogaeva E, Bugiani O, Giaccone G, Foncin JF, Spillantini MG, Puccio G * Worldwide distribution of PSEN1 Met146Leu mutation: A large variability for a founder mutation(409 visite) Neurology (ISSN: 0028-3878, 1526-632x, 1526-632xelectronic), 2010 Mar 9; 74(10): 798-806. Impact Factor:8.017 DettagliEsporta in BibTeXEsporta in EndNote
Hesse B, Tagil K, Cuocolo A, Anagnostopoulos C, Bardies M, Bax J, Bengel F, Busemann Sokole E, Davies G, Dondi M, Edenbrandt L, Franken P, Kjaer A, Knuuti J, Lassmann M, Ljungberg M, Marcassa C, Marie PY, Mckiddie F, O'connor M, Prvuolovich E, Underwood R * 3. 0 T perfusion MR imaging(551 visite) Rivista Di Neuroradiologia (ISSN: 1120-9976), 2004; 17(6): 807-812. Impact Factor:0.023 DettagliEsporta in BibTeXEsporta in EndNote